Risk of lymphoma in inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 5, Issue 11, 2009, Pages 784-790

  Siegel, Corey A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Anti tumor necrosis factor; Crohn's disease; Immunomodulator; Inflammatory bowel disease; Lymphoma; Ulcerative colitis

Indexed keywords

IMMUNOMODULATING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

CANCER RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PRESCRIPTION; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; ULCERATIVE COLITIS;

EID: 72949103340     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J. 2000;1:53-66.
2. National Cancer Institute. Surveillance, Epidemiology, and End Results Database [database]. Available at: http://seer.cancer.gov. Accessed on July 28, 2009.
3. Bargen JA. Chronic ulcerative colitis associated with malignant disease. Arch Surg. 1928;17:561-576.
4. National Cancer Institute. Histiocytic lymphoma [dictionary entry]. Available at: http://www.cancer.gov/Templates/db-alpha.aspx?CdrID=373019. Accessed July 28, 2009.
5. Hughes RK. Reticulum cell sarcoma: a case possibly originating in regional enteritis. Am Surg. 1955;21:770-773.
6. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080-1087. (Pubitemid 33022087)
7. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862. (Pubitemid 32173312)
8. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015-2019.
9. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extraintestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004;19:287-293.
10. Karlen P, Lofberg R, Brostrom O, Leijonmarck CE, Hellers G, Persson PG. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94:1047-1052. (Pubitemid 29173626)
11. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308-2312. (Pubitemid 30707393)
12. Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647-653. (Pubitemid 30681123)
13. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Broström O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994;107:1675-1679. (Pubitemid 24357620)
14. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088-1095. (Pubitemid 40037640)
15. Farrell RJ, Ang Y, Kileen P, O'Briain DS, Kelleher D, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
16. Greenstein AJ, Mullin GE, Strauchen JA, Heimann T, Janowitz HD, et al. Lymphoma in inflammatory bowel disease. Cancer. 1992;69:1119-1123.
17. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 2004;16:254-261.
18. Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-622. (Pubitemid 40559243)
19. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979;2:1461-1466.
20. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985;78:44-49. (Pubitemid 15167365)
21. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother. 2007;41:1850-1858.
22. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoprolifcrative disorder using preemptive antiviral therapy. Transplantation. 1997;64:848-852.
23. Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren's syndrome: case series. J Rheumatol. 2001;28:47-53. (Pubitemid 32062024)
24. Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72-77.
25. Hecker R, Sheers R, Thomas D. Hodgkin's disease as a complication of Crohn's disease. Med J Aust. 1978;2:603.
26. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-1252. (Pubitemid 24158045)
27. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16:1225-1232. (Pubitemid 34888353)
28. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125. (Pubitemid 41025906)
29. Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999;94:3248-3253.
30. Beaugerie L, Carrat F, Bouvier AM, Brousse N, Carbonnel F, et al. Excess risk of lymphoprolifcrative disorders (LPD) in inflammatory bowel diseases (IBD): Interim results of the CESAME cohort. Gastroenterology. 2008;134:A-116.
31. Lemann M, de La Valussiere G, Bouhnik Y, Allez M, Touze Y, et al. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): Long-term follow-up of patients. Gastroenterology. 1998;114:A1020.
32. Mittal S, Milner BJ, Johnston PW, Culligan DJ. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol. 2006;76:531-534.
33. Navarro JT, Ribera JM, Mate JL, Granada I, Juncà J, et al. Hepatosplenic T-gamma delta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma. 2003;44:531-533. (Pubitemid 36113901)
34. Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59:794-799. (Pubitemid 351847561)
35. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433-1439. (Pubitemid 46764070)
36. Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, et al. Rheumatoid arthritis, treatment with corticosteroids, and risk of malignant lymphomas - results from a case-control study. Ann Rheum Dis. 2009. May 12. [Epub ahead of print].
37. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
38. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653. (Pubitemid 351783447)
39. Siegel CA, Maiden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
40. Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1-6.
41. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769-779. (Pubitemid 47374126)
42. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018-1024.
43. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1017-1024. (Pubitemid 44137437)